Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts
Summary:
We are seeking a highly motivated and detail-oriented Corporate & Securities Counsel to join our growing legal team. You will play a critical role in supporting the company’s public company reporting obligations and broader corporate governance needs. Further, you will provide strategic legal guidance on complex corporate matters and partner with senior executives to drive business objectives. The ideal candidate will bring strong securities law experience from a top law firm and/or in-house legal department, with the ability to independently manage SEC filings and contribute to a range of corporate legal matters. In addition, this role will provide general legal support to the legal team and assist with other matters as they arise, consistent with the needs of the department.
Your role:
- Prepare and review periodic and current reports, including Forms 10-K, 10-Q, and 8-K, proxy statements, and Section 16 filings (Forms 3, 4, and 5)
- Support corporate governance matters, including board and committee preparation and maintenance of governance policies and practices
- Assist with disclosure planning and drafting, including earnings releases, investor presentations, and the annual proxy statement
- Advise on securities law compliance, Nasdaq listing standards, and insider trading matters
- Provide legal support for corporate transactions, including financings and equity offerings
- Support cross-functional teams on general corporate matters
- Collaborate with external counsel and internal teams including Finance, Investor Relations, and HR
- Provide training to internal stakeholders on legal, compliance, and contracting best practices
- Partner with internal audit and compliance functions to monitor risk and implement mitigation strategies.
What you bring:
- J.D. from an accredited law school and admitted to practice in at least one U.S. jurisdiction
- A minimum of 6-8 years of securities law experience at a top-tier law firm and/or in a public biotech company’s legal department
- Deep knowledge of SEC rules and regulations, Sarbanes-Oxley, listing exchange requirements, and other applicable laws and regulations
- General corporate background and familiarity with equity plans and executive compensation is a plus
- Ability to interpret legal requirements and deliver pragmatic, business-oriented guidance
- Proven capability to manage multiple priorities in a fast-paced, collaborative environment
- Ability to thrive in a team setting and a desire to be innovative in rapidly evolving and fast-paced company
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Top Skills
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
